Logos Global Management’s Travere Therapeutics TVTX Stock Holding History

Logos Global Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000,000	Closed	-$17.4M	–	55
2024 Q4	$17.4M	Sell	1,000,000 -100,000	-9%	-$1.77M	2.04%	19
2024 Q3	$15.4M	Buy	+1,100,000	New	+$11.5M	1.66%	24
2022 Q1	–	Sell	-100,000	Closed	-$3.1M	–	63
2021 Q4	$3.1M	Buy	+100,000	New	+$2.82M	0.32%	52
2021 Q1	–	Sell	-61,152	Closed	-$1.67M	–	73
2020 Q4	$1.67M	Buy	+61,152	New	+$1.43M	0.14%	54

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Logos Global Management's TVTX Position: Q1 2025 in Review

Logos Global Management sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 1,000,000 shares — an estimated $17.4M sold.

Logos Global Management first reported a position in TVTX in Q4 2020 and held it in 4 quarters. The position peaked at $17.4M in Q4 2024. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

Logos Global Management reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
Logos Global Management sold 1,000,000 Travere Therapeutics shares in Q1 2025, an estimated $17.4M.
Logos Global Management first reported a position in Travere Therapeutics in Q4 2020 and held it in 4 quarters.
Logos Global Management's Travere Therapeutics position peaked at $17.4M in Q4 2024.
218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Logos Global Management's 13F filing for Q1 2025, filed 15 May 2025.